ENZO BIOCHEM, INC. Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
ENZO BIOCHEM, INC. reported Net Income (Loss), Including Portion Attributable to Noncontrolling Interest of -$2.65 million for the 3-month period ending 2022-01-31, per its 10-Q filed 2022-03-14.
Discontinued › Income Statement
us-gaap:ProfitLoss · last filed 2022-03-14
- ENZO BIOCHEM, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2022-01-31 was -$2.65M, a 215.33% decline year-over-year.
- ENZO BIOCHEM, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2021-10-31 was -$2.32M, a 875.59% decline year-over-year.
- ENZO BIOCHEM, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2021-07-31 was $3.27M.
- ENZO BIOCHEM, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2021-04-30 was $2.01M.
- ENZO BIOCHEM, INC. net income (loss), including portion attributable to noncontrolling interest for fiscal 2021 was $7.88M.
- ENZO BIOCHEM, INC. net income (loss), including portion attributable to noncontrolling interest for fiscal 2020 was -$28.52M, a 1245.84% decline from fiscal 2019.
- ENZO BIOCHEM, INC. net income (loss), including portion attributable to noncontrolling interest for fiscal 2019 was $2.49M.
| Period end | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 3 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 6 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 9 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2022-01-31 | -$2.65M 10-Q · filed 2022-03-14 | -$4.97M 10-Q · filed 2022-03-14 | -$1.71M derived: sum of 3 quarters · filed 2022-03-14 | $300.00K derived: sum of 4 quarters · filed 2022-03-14 |
| 2021-10-31 | -$2.32M 10-Q · filed 2021-12-15 | $949.00K derived: sum of 2 quarters · filed 2021-12-15 | $2.96M derived: sum of 3 quarters · filed 2021-12-15 | $5.26M derived: sum of 4 quarters · filed 2022-03-14 |
| 2021-07-31 | $3.27M derived: 10-K 12 month − 10-Q 9 month · filed 2021-10-12 | $5.27M derived: sum of 2 quarters · filed 2021-10-12 | $7.58M derived: sum of 3 quarters · filed 2022-03-14 | $7.88M 10-K · filed 2021-10-12 |
| 2021-04-30 | $2.01M 10-Q · filed 2021-06-11 | $4.31M derived: sum of 2 quarters · filed 2022-03-14 | $4.61M 10-Q · filed 2021-06-11 | $1.28M derived: sum of 4 quarters · filed 2022-03-14 |
| 2021-01-31 | $2.30M 10-Q · filed 2022-03-14 | $2.60M 10-Q · filed 2022-03-14 | -$724.00K derived: sum of 3 quarters · filed 2022-03-14 | -$10.58M derived: sum of 4 quarters · filed 2022-03-14 |
| 2020-10-31 | $299.00K 10-Q · filed 2021-12-15 | -$3.03M derived: sum of 2 quarters · filed 2021-12-15 | -$12.89M derived: sum of 3 quarters · filed 2021-12-15 | |
| 2020-07-31 | -$3.33M derived: 10-K 12 month − 10-Q 9 month · filed 2021-10-12 | -$13.19M derived: sum of 2 quarters · filed 2021-10-12 | -$28.52M 10-K · filed 2021-10-12 | |
| 2020-04-30 | -$9.86M 10-Q · filed 2021-06-11 | -$25.20M 10-Q · filed 2021-06-11 | ||
| 2019-07-31 | $2.49M 10-K · filed 2021-10-12 |